NasdaqGS:AMRXPharmaceuticals
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection
Amneal Pharmaceuticals (AMRX) just secured FDA approval for its 1 mg/mL epinephrine injection in single and multi dose vials, plugging into a critical hospital therapy market with roughly $118 million in U.S. annual sales.
See our latest analysis for Amneal Pharmaceuticals.
The FDA approval lands as Amneal’s share price sits at $12.57 and recent momentum has been strong, with a roughly 62 percent year to date share price return and a powerful multi year total shareholder return backing the...